Abstract: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. In preferred embodiments, the F-18 label may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety, such as DOTA, NOTA, DTPA, TETA or NETA. In other embodiments, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen.
Type:
Application
Filed:
December 19, 2007
Publication date:
July 17, 2008
Applicant:
IMMUNOMEDICS, INC.
Inventors:
William J. McBride, David M. Goldenberg
Abstract: The present application discloses methods for myocardial imaging in human patients having a history of pulmonary disease such as asthma, bronchospasm, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary inflammation, or pulmonary hypertension, comprising administrating doses of one or more A2A adenosine receptor agonists to a mammal undergoing myocardial imaging and detecting and/or diagnosing myocardial dysfunction.
Type:
Application
Filed:
September 28, 2007
Publication date:
July 17, 2008
Applicant:
CV THERAPEUTICS, INC.
Inventors:
Hsiao D. Lieu, Brent Blackburn, Luiz Belardinelli
Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
Type:
Application
Filed:
September 6, 2007
Publication date:
July 17, 2008
Inventors:
Wenyuan Shi, Randal H. Eckert, Daniel K. Yarbrough, Fengxia Qi, Jian He, Ian H. McHardy, Maxwell H. Anderson
Abstract: The present application is directed to radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
Type:
Application
Filed:
September 17, 2007
Publication date:
July 17, 2008
Inventors:
Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Qianwa Liang, Henry Clifton Padgett, Farhad Karimi
Abstract: The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.
Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
Abstract: Embodiments of the invention include compositions, formulations and methods for the enhancement of a subject's biological defenses against infection, for example the subject's innate immunity against infection. Aspects of the invention provide a rapid and temporal enhancement or augmentation of biological defenses against microbial infection.
Type:
Application
Filed:
July 30, 2007
Publication date:
July 17, 2008
Applicant:
The Board of Regents of the University of Texas System
Inventors:
Burton F. Dickey, Michael Tuvim, Cecilia G. Clement
Abstract: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as alkyl selenols. Preferred compositions employ R—Se—Se—R compounds where R is from 6 to 8 carbon atoms, and most specifically di-n-hexyl diselenide. Commonly used carriers may be purified hydrocarbon fractions, oils, with or without added fat-soluble vitamins, water and emulsifying agents.
Abstract: The invention relates to a composition for treating or preventing an oral cavity by preventing adhesion of Porphyromonas gingivalis as periodontopathic bacterium to oral tissue. The invention also relates to a composition for treating or preventing an oral cavity containing a peptide in which arginine and histidine bind alternately. Preferably, the invention includes a composition for treating or preventing an oral cavity including the peptide of a pentamer of (arginine-histidine).
Type:
Application
Filed:
February 26, 2008
Publication date:
July 17, 2008
Inventors:
Satoshi Shizukuishi, Hideki Nagata, Jun Hiraki, Masami Todokoro
Abstract: Use of a compound of formula (I) where R1 is a C4-6 alkylene linkage optionally substituted by a C1-4alkyl group; R2 is ?NH, —NH2 or —OH; R3 is C1-5 alkyl optionally terminated by a hydroxy, phenyl or a 5- or 6-membered heterocyclic group such as furyl or N-imidazolyl and R4 is H; or R3 and R4 together form a C3-5 alkylene linkage; to produce a topical refreshing or cooling sensation in a mammal such as a human.
Type:
Application
Filed:
November 7, 2005
Publication date:
July 17, 2008
Inventors:
Alison Jayne Foster, Cornelis Paul Erik Van De Logt, Afrodite Lourbakos, Erwin Werner Tareilus
Abstract: The present invention is directed to a tooth surface mineralizing composition including a stabilized tooth mineralizing mineral composition containing calcium and phosphate and a dissociable source of a mineral that provides a mineral ionic species selected from calcium and phosphate upon dissociation.
Type:
Application
Filed:
January 11, 2008
Publication date:
July 17, 2008
Inventors:
Emil E. Engelman, Robert J. Gambogi, Deepak Sharma
Abstract: The present invention is directed to a tooth cleaning and mineralizing composition including an abrasive composition in an amount sufficient to provide the tooth cleaning and mineralizing composition with a relative dental abrasion of from 100 to 250; and a stabilized tooth mineralizing mineral composition.
Type:
Application
Filed:
January 11, 2008
Publication date:
July 17, 2008
Inventors:
Emil E. Engelman, Robert J. Gambogi, Deepak Sharma
Abstract: Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.
Type:
Application
Filed:
July 20, 2007
Publication date:
July 17, 2008
Applicant:
GOURMETCEUTICALS, LLC
Inventors:
Jose Antonio Matji Tuduri, Antonio F. Guerrero Gomez-Pamo, Jose Luis Alonso Lebrero, Garrett Lindemann, Manuel Lopez Cabrera, Pedro Majano Rodriguez, Ricardo Moreno Otero, Diego Serrano Gomez, Angel Corbi Lopez, Samuel Martin Vilchez
Abstract: The present invention discloses a process of preparing jambu extract that results in a jambu extract free from chlorophyll and derivatives of this compound. It is a method for isolating the components of interest in a simplified way, with quite high process yield, higher than 85%. The present invention further relates to the use of this extract in preparing cosmetic compositions, the cosmetic compositions comprising said extract, and to cosmetic products comprising said cosmetic compositions.
Abstract: The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.
Abstract: Disclosed herein is a composition for make-up and/or care of the skin comprising a fatty phase, comprising: at least one resin of number average molecular weight less than or equal to 10,000 g/mol, selected from rosin, derivatives of rosin, and hydrocarbon resins, at least one hydrocarbon block copolymer, at least one fatty substance whose melting point is greater than 25° C. chosen from waxes and pasty fatty substances, wherein said composition comprises less than 5% of volatile oil.
Type:
Application
Filed:
December 19, 2007
Publication date:
July 17, 2008
Inventors:
Veronique Jacques, Veronique Schwartz, Xavier Blin, Philippe Ilekti
Abstract: The present invention is directed to a method of making up keratinous substrates involving applying onto the keratinous substrate a composition containing a) a block copolymer, b) a tackifier, c) an alkyl silsesquioxane wax, d) a liquid fatty phase, and e) optionally, a colorant.
Type:
Application
Filed:
January 10, 2008
Publication date:
July 17, 2008
Applicant:
L'OREAL
Inventors:
Hy Si BUI, Ann Marie Rohmeyer, Padraig McDermott
Abstract: A method of making up keratinous substrates involving applying onto the keratinous substrates a composition containing a) a block copolymer, b) a tackifier, c) a wax, d) a liquid fatty phase, e) a high viscosity ester, and f) optionally, a colorant.
Abstract: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising (a) at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form of graft, and at least two groups capable of establishing hydrogen interactions; (b) at least one tackifier; (c) at least one block copolymer; and (d) at least one wax, as well as to methods of using such compositions and kits containing such compositions.
Abstract: Keratin fibre makeup kit containing at least: a first composition with a surface energy of less than or equal to 30 mN/m, and a second composition with a surface energy such that the difference between its surface energy and that of the first composition is greater than or equal to 5 mN/m, and a viscosity of between 0.001 and 2 Pa·s.
Abstract: The present disclosure relates to a treatment of the hair, which is resistant to shampooing operations, wherein the individual hairs are coated with a cosmetic composition comprising a polysiloxane/polyurea block copolymer wherein at least one volatile nonsilicone organic solvent and at least one silicone compound exhibit a viscosity of less than 100 cSt.
Abstract: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.
Abstract: The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.
Type:
Application
Filed:
January 10, 2008
Publication date:
July 17, 2008
Inventors:
Phillip Messersmith, Andrea R. Statz, Bruce P. Lee, Jeffrey L. Dalsin, Daniel Sherman
Abstract: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
Type:
Application
Filed:
September 7, 2007
Publication date:
July 17, 2008
Inventors:
Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Type:
Application
Filed:
January 9, 2008
Publication date:
July 17, 2008
Inventors:
John A. Bender, Min Ding, Robert G. Gentles
Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
Type:
Application
Filed:
March 11, 2008
Publication date:
July 17, 2008
Applicant:
Human Genome Sciences, Inc.
Inventors:
Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
Abstract: A method for the treatment of proliferative disease or infectious disease, comprising administering to the patient an effective amount of a CD25 binding molecule.
Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.
Type:
Application
Filed:
October 29, 2007
Publication date:
July 17, 2008
Applicant:
Crucell Holland B.V.
Inventors:
Abraham Bout, Menzo Havenga, Ronald Vogels
Abstract: The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages, that are isolated, processed and cryopreserved, and the therapeutic uses of such stem and progenitor cells upon application. Such compositions may be useful for hematopoietic reconstitution and/or replacement in patients with various diseases and metabolic disorders. The invention also relates to methods for collecting, isolating, processing and cryopreserving of the fetal stem and progenitor cells of the invention. Importantly, the invention meets an urgent need in regenerative medicine while at the same time ensures utility of the product compositions because it utilizes fetal materials from second trimester (16-20 weeks of gestation) spontaneously lost pregnancies which are free of moral or ethical burdens.
Abstract: The present invention is directed to the expansion, preferably TVEMF-expansion, of mammalian blood adult stem cells, wherein the expansion takes place in a rotating bioreactor, preferably a TVEMF-bioreactor, to compositions resulting from the expanded cells, and to a method of treating an epithelial cell/tissue related disease or condition or repairing tissue of skin, mouth or ear with the compositions.
Abstract: The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 17, 2008
Applicants:
Beth Israel Deaconess Medical Center, Inc., University of Pittsburgh of the Commonwealth System of Higher Education
Abstract: Methods and systems are provided to facilitate treatment for a neoplastic disease include providing information of stem cells that can be isolated from an individual prior to diagnosis with a neoplastic disease; processing and storing the stem cells, such as cord blood or bone marrow stem cells, in a format suitable for transfusion; providing information that treatment of the individual after diagnosis with the neoplastic disease includes bone marrow ablation in addition to at least one of surgery, chemotherapy, and radiation therapy; and releasing the stem cells for administration to the individual to repopulate the bone marrow after ablation.
Abstract: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a cancer patient to activate a predominantly CD8+T cell response in vivo. In an alternate embodiment, human dendritic cells are exposed to a tumor associated antigen or a specific antigenic peptide in combination with BCG in vitro and incubated or cultured with primed or unprimed T cells to activate a predominantly CD8+T cell response in vitro. The activated T cells are then administered to a cancer patient. Antigen in combination with BCG is processed by dendritic cells through the MHC-CLASS I compartment which provides for a predominantly CD8+T cell response.
Abstract: A method for preventing bacterial biofilm formation in a blood product, the method comprising modifying a blood product with a polymer selected from the group consisting of polyethylene glycol (PEG), PEG derivatives and mixtures thereof. Preventing bacterial biofilm formation in this way increases the planktonic to adherent ratio of any contaminating bacteria, and thereby facilitates detection of bacterial contamination.
Type:
Application
Filed:
December 21, 2007
Publication date:
July 17, 2008
Inventors:
Sandra M. Ramirez-Arcos, Elisabeth Maurer, Mark Scott
Abstract: The present invention is directed to methods of transfecting cells with siRNA, by contacting a transfection complex with one or more cells, where the transfection complex includes a transport polymer and siRNA. The transport polymer may include for example, H3K8b and/or structurally similar compounds. The invention is also directed to such transfection complexes, and to compositions that include such transfection complexes. The invention is further directed to methods of treating patients using the transfection complexes of the present invention.
Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 17, 2008
Inventors:
Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francis-Loic Cosset, Roberto Cattaneo
Abstract: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 17, 2008
Inventors:
Stephen James Russell, Frances Joanne Morling, Adele Kay Fielding, Francois-Loic Cosset, Roberto Cattaneo
Abstract: Microbial starter cultures. More specifically, a method for preparing a microbial starter culture wherein the microorganism is inoculated in a culture medium comprising at least one 5 yield enhancing agent selected from the group consisting of a purine base, a pyrimidine base, a nucleoside and a nucleotide. Such microbial starter cultures are useful in the manufacturing of food, feed and pharmaceutical products.
Type:
Application
Filed:
January 5, 2006
Publication date:
July 17, 2008
Inventors:
Borge Windel Kringelum, Niels Martin Sorensen, Christel Garrigues, Martin B. Pedersen, Susanne Gron
Abstract: A beauty mask uses natural material, like coconut milk, royal jelly, vegetable enzymes, aloe and loofah, for achieving a whitening, anti-wrinkle and moisturizing effect without further additives, thereby avoiding skin injuries, and which can be stored for a long time; furthermore a method for packing and storing beauty masks, by inserting separating foils between beauty masks and comprising steps of packing, sealing and freezing, prevents beauty masks from sticking together, so that beauty masks are storable for a long time and easily dispensable.
Abstract: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.
Abstract: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.
Abstract: Described are compositions comprising a combination of superoxide dismutase and at least one member selected from the group consisting of astaxanthin, tocotrienol, carnosine, and benfotiamine, and methods of using the same for ameliorating or preventing the detrimental effects of oxidative stress.
Abstract: Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or a biologically active derivative thereof. Additionally, the invention relates to methods for treating a disease associated with and/or progresses by an inflammatory cytokine-associated inflammation and/or VEGF-associated angiogenesis.
Abstract: Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein.
Abstract: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.
Type:
Application
Filed:
January 25, 2008
Publication date:
July 17, 2008
Applicant:
SCHERING CORPORATION
Inventors:
Alexander B.H. Bakker, Joseph H. Phillips, Lewis L. Lanier
Abstract: TACI receptor antibodies are provided. The TACI antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the TACI antibodies are also provided.
Type:
Application
Filed:
August 20, 2007
Publication date:
July 17, 2008
Inventors:
Anan Chuntharapai, Iqbal Grewal, Kyung Jin Kim, Minhong Yan
Abstract: A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided. Nucleic acid molecules encoding Apo-3 Ligand, chimeric molecules and antibodies to Apo-3 Ligand are also provided.
Type:
Application
Filed:
August 7, 2007
Publication date:
July 17, 2008
Inventors:
Avi J. Ashkenazi, Scot A. Marsters, Robert Pitti
Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of Idiopathic Thrombocytopenia Purpura (ITP). Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has ITP and pharmaceutical compositions comprising such antagonists.
Type:
Application
Filed:
November 8, 2007
Publication date:
July 17, 2008
Applicant:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Geoffrey T. Yarranton